Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 215

1.

The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.

Schoepfer AM, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, Fournier N, Vader JP, Burnand B, Michetti P, Froehlich F.

Aliment Pharmacol Ther. 2014 Oct;40(8):930-7. doi: 10.1111/apt.12929. Epub 2014 Aug 22.

2.

Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.

Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Aug;8(8):825-34. doi: 10.1016/j.crohns.2013.12.026. Epub 2014 Jan 22.

PMID:
24462322
3.

Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.

Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; Swiss Inflammatory Bowel Disease Cohort Study Group.

Digestion. 2013;87(3):212-21. doi: 10.1159/000350954. Epub 2013 May 23.

PMID:
23711401
4.

When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.

Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACT-II Update Panellists.

J Crohns Colitis. 2013 Nov;7(10):820-6. doi: 10.1016/j.crohns.2013.04.013. Epub 2013 May 9.

PMID:
23664620
5.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

6.

Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II.

Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):257-63. doi: 10.1016/j.crohns.2009.03.008. Epub 2009 May 14.

PMID:
21172284
7.

Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II.

Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F, Michetti P; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):250-6. doi: 10.1016/j.crohns.2009.06.001. Epub 2009 Aug 22.

PMID:
21172283
8.

Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II.

Juillerat P, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Bemelman WA, Lémann M, Oresland T, Michetti P, Froehlich F; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):241-9. doi: 10.1016/j.crohns.2009.05.002. Epub 2009 Jul 14.

PMID:
21172282
9.

Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II.

Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):232-40. doi: 10.1016/j.crohns.2009.05.003. Epub 2009 Jul 15.

PMID:
21172281
10.

Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group.

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1352-7. Erratum in: Eur J Gastroenterol Hepatol. 2011 Mar;23(3):294. Tempia-Caliera, Michela [corrected to Schäppi, Michela].

PMID:
20964261
11.

Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.

Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2010 Oct;32(8):1007-16. doi: 10.1111/j.1365-2036.2010.04434.x. Epub 2010 Aug 18.

12.

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.

Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators.

Hepatology. 2010 Oct;52(4):1201-7. doi: 10.1002/hep.23816.

PMID:
20683847
13.

Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort.

Juillerat P, Pittet V, Mottet C, Felley C, Gonvers JJ, Vader JP, Burnand B, Froehlich F, Wolters FL, Stockbrügger RW, Michetti P; EC-IBD Group.

Scand J Gastroenterol. 2010 Dec;45(12):1449-56. doi: 10.3109/00365521.2010.505660. Epub 2010 Jul 26.

PMID:
20653489
14.

Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.

Gonvers JJ, Heim MH, Cavassini M, Müllhaupt B, Genné D, Bernasconi E, Borovicka J, Cerny A, Chave JP, Chuard C, Dufour F, Dutoit V, Malinverni R, Monnat M, Negro F, Troilliet N, Oneta C.

Swiss Med Wkly. 2010 Jul 19;140:w13055. doi: 10.4414/smw.2010.13055.

PMID:
20648398
15.

The effect of nonmedical factors on variations in the performance of colonoscopy among different health care settings.

Lamiraud K, Holly A, Burnand B, Juillerat P, Wietlisbach V, Froehlich F, Gonvers JJ, Vader JP.

Med Care. 2010 Feb;48(2):101-9. doi: 10.1097/MLR.0b013e3181c160ee.

PMID:
20068487
16.

Appropriateness of colonoscopy in Europe (EPAGE II). Presentation of methodology, general results, and analysis of complications.

Juillerat P, Peytremann-Bridevaux I, Vader JP, Arditi C, Schusselé Filliettaz S, Dubois RW, Gonvers JJ, Froehlich F, Burnand B, Pittet V.

Endoscopy. 2009 Mar;41(3):240-6. doi: 10.1055/s-0028-1119643. Epub 2009 Mar 11. Review.

PMID:
19280536
17.

Appropriateness of colonoscopy in Europe (EPAGE II). Functional bowel disorders: pain, constipation and bloating.

Schusselé Filliettaz S, Gonvers JJ, Peytremann-Bridevaux I, Arditi C, Delvaux M, Numans ME, Lorenzo-Zúñiga V, Dubois RW, Juillerat P, Burnand B, Pittet V, Vader JP, Froehlich F; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):234-9. doi: 10.1055/s-0028-1119625. Epub 2009 Mar 11. Review.

PMID:
19280535
18.

Appropriateness of colonoscopy in Europe (EPAGE II). Iron-deficiency anemia and hematochezia.

Peytremann-Bridevaux I, Arditi C, Froehlich F, O'Malley J, Fairclough P, Le Moine O, Dubois RW, Gonvers JJ, Schusselé Filliettaz S, Vader JP, Juillerat P, Pittet V, Burnand B; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):227-33. doi: 10.1055/s-0028-1119644. Epub 2009 Mar 11. Review.

PMID:
19280534
19.

Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease.

Schusselé Filliettaz S, Juillerat P, Burnand B, Arditi C, Windsor A, Beglinger C, Dubois RW, Peytremann-Bridevaux I, Pittet V, Gonvers JJ, Froehlich F, Vader JP; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):218-26. doi: 10.1055/s-0028-1119627. Epub 2009 Mar 11. Review.

PMID:
19280533
20.

Appropriateness of colonoscopy in Europe (EPAGE II). Surveillance after polypectomy and after resection of colorectal cancer.

Arditi C, Gonvers JJ, Burnand B, Minoli G, Oertli D, Lacaine F, Dubois RW, Vader JP, Schusselé Filliettaz S, Peytremann-Bridevaux I, Pittet V, Juillerat P, Froehlich F; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):209-17. doi: 10.1055/s-0028-1119646. Epub 2009 Mar 11. Review.

PMID:
19280532

Supplemental Content

Loading ...
Support Center